Karyopharm Therapeutics (KPTI) Current Assets (2012 - 2025)

Karyopharm Therapeutics has reported Current Assets for 14 years, with the latest figure at $103.1 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets fell 34.08% year-over-year to $103.1 million; the trailing twelve-month figure through Dec 2025 stood at $103.1 million (down 34.08% YoY), and the FY2025 full-year result was $103.1 million, down 34.08% from the prior year.
• Current Assets for Q4 2025 stood at $103.1 million, up from $89.7 million in the prior quarter.
• The five-year high for Current Assets was $350.2 million in Q4 2022, with the low at $89.7 million in Q3 2025.
• Historically, Current Assets has averaged $220.2 million across 5 years, with a median of $237.8 million in 2021.
• Annual changes were most pronounced in 2022 — Current Assets grew 27.05% — and 2025, when it plunged 53.07%.
• Karyopharm Therapeutics' Current Assets stood at $275.6 million in 2021, then increased by 27.05% to $350.2 million in 2022, then slumped by 33.2% to $233.9 million in 2023, then plunged by 33.11% to $156.5 million in 2024, then plunged by 34.08% to $103.1 million in 2025.
• The last three Current Assets figures came in at $103.1 million (Q4 2025), $89.7 million (Q3 2025), and $97.9 million (Q2 2025), per Business Quant data.